To the Editor: In their article in the January 1 issue, Ingle et al.1 stated that in four of 11 patients who had tumor regression and subsequent reactivation during treatment with diethylstilbestrol (DES), withdrawal reactions were observed after discontinuation of this drug. Patients in whom DES failed and patients first treated with tamoxifen were not entered into a withdrawal phase but were subsequently treated with tamoxifen or DES. In the discussion, the authors speculate that some of the tumor regressions observed during subsequent DES treatment were in fact withdrawal responses to discontinuation of tamoxifen. In a randomized trial we compared.
ASJC Scopus subject areas